These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 7568181)

  • 1. Expression of lactoferrin receptors is increased in the mesencephalon of patients with Parkinson disease.
    Faucheux BA; Nillesse N; Damier P; Spik G; Mouatt-Prigent A; Pierce A; Leveugle B; Kubis N; Hauw JJ; Agid Y
    Proc Natl Acad Sci U S A; 1995 Oct; 92(21):9603-7. PubMed ID: 7568181
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cellular distribution of the iron-binding protein lactotransferrin in the mesencephalon of Parkinson's disease cases.
    Leveugle B; Faucheux BA; Bouras C; Nillesse N; Spik G; Hirsch EC; Agid Y; Hof PR
    Acta Neuropathol; 1996; 91(6):566-72. PubMed ID: 8781654
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Iron metabolism and Parkinson's disease.
    Hirsch EC; Faucheux BA
    Mov Disord; 1998; 13 Suppl 1():39-45. PubMed ID: 9613717
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The protective effect of lactoferrin on ventral mesencephalon neurons against MPP + is not connected with its iron binding ability.
    Wang J; Bi M; Liu H; Song N; Xie J
    Sci Rep; 2015 Jun; 5():10729. PubMed ID: 26035688
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Iron transport in Parkinson's disease.
    Hirsch EC
    Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 3():S209-11. PubMed ID: 20082992
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The iron-binding protein lactoferrin protects vulnerable dopamine neurons from degeneration by preserving mitochondrial calcium homeostasis.
    Rousseau E; Michel PP; Hirsch EC
    Mol Pharmacol; 2013 Dec; 84(6):888-98. PubMed ID: 24077968
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The density of [125I]-transferrin binding sites on perikarya of melanized neurons of the substantia nigra is decreased in Parkinson's disease.
    Faucheux BA; Hauw JJ; Agid Y; Hirsch EC
    Brain Res; 1997 Feb; 749(1):170-4. PubMed ID: 9070646
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alterations in the distribution of glutathione in the substantia nigra in Parkinson's disease.
    Pearce RK; Owen A; Daniel S; Jenner P; Marsden CD
    J Neural Transm (Vienna); 1997; 104(6-7):661-77. PubMed ID: 9444566
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intrapallidal lipopolysaccharide injection increases iron and ferritin levels in glia of the rat substantia nigra and induces locomotor deficits.
    Zhang J; Stanton DM; Nguyen XV; Liu M; Zhang Z; Gash D; Bing G
    Neuroscience; 2005; 135(3):829-38. PubMed ID: 16165292
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease.
    Yoritaka A; Hattori N; Uchida K; Tanaka M; Stadtman ER; Mizuno Y
    Proc Natl Acad Sci U S A; 1996 Apr; 93(7):2696-701. PubMed ID: 8610103
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impaired iron homeostasis in Parkinson's disease.
    Double KL; Gerlach M; Youdim MB; Riederer P
    J Neural Transm Suppl; 2000; (60):37-58. PubMed ID: 11205155
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The nucleolus of the cell is the site of iron accumulation in the substantia nigra neurons of the human brain].
    Sukhorukova YG; Grigoriev IP; Kolos YA; Korzhenevskiy DE
    Morfologiia; 2012; 142(6):61-2. PubMed ID: 23659042
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Distribution of 125I-ferrotransferrin binding sites in the mesencephalon of control subjects and patients with Parkinson's disease.
    Faucheux BA; Hirsch EC; Villares J; Selimi F; Mouatt-Prigent A; Javoy-Agid F; Hauw JJ; Agid Y
    J Neurochem; 1993 Jun; 60(6):2338-41. PubMed ID: 8492137
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does oxidative stress participate in nerve cell death in Parkinson's disease?
    Hirsch EC
    Eur Neurol; 1993; 33 Suppl 1():52-9. PubMed ID: 8375433
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transferrin receptors in the parkinsonian midbrain.
    Morris CM; Candy JM; Omar S; Bloxham CA; Edwardson JA
    Neuropathol Appl Neurobiol; 1994 Oct; 20(5):468-72. PubMed ID: 7845532
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Apolipoprotein D expression in substantia nigra of Parkinson disease.
    Ordoñez C; Navarro A; Perez C; Astudillo A; Martínez E; Tolivia J
    Histol Histopathol; 2006 Apr; 21(4):361-6. PubMed ID: 16437381
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regional dopamine transporter gene expression in the substantia nigra from control and Parkinson's disease brains.
    Counihan TJ; Penney JB
    J Neurol Neurosurg Psychiatry; 1998 Aug; 65(2):164-9. PubMed ID: 9703165
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An ultrastructural double-label immunohistochemical study of the enkephalinergic input to dopaminergic neurons of the substantia nigra in pigeons.
    Medina L; Anderson KD; Karle EJ; Reiner A
    J Comp Neurol; 1995 Jul; 357(3):408-32. PubMed ID: 7673476
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glial pathology but absence of apoptotic nigral neurons in long-standing Parkinson's disease.
    Banati RB; Daniel SE; Blunt SB
    Mov Disord; 1998 Mar; 13(2):221-7. PubMed ID: 9539333
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease.
    Halliday GM; Ophof A; Broe M; Jensen PH; Kettle E; Fedorow H; Cartwright MI; Griffiths FM; Shepherd CE; Double KL
    Brain; 2005 Nov; 128(Pt 11):2654-64. PubMed ID: 16000336
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.